Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: TRPV1 is required for pelvic pain. (A-B) Graphs show response frequencies measured with von Frey filaments applied to C57BL/6J (B6) mice and TRPV1 KO mice at days 0, 7, 14, and 20. (A) B6 mice with EAP (n=10) develop increased pelvic tactile allodynia compared to naive (n=10) mice at days 7, 14, and 20; (B) however, mice lacking the TRPV1 channel with EAP (TRPV1 KO-EAP; n=7) do not show a change in pelvic tactile allodynia at any time point, compared to respective control (TRPV1 KO-Naive; n=8). Data represents the mean ± SEM and was generated from three independent experiments. (*) denotes P<0.05.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Control, Generated

Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: Absence of TRPV1 does not change prostate inflammation. (A,C) Representative images and (B,D) relative quantification of prostate inflammation in the dorsal and lateral prostate (DLP), ventral prostate (VP), and anterior prostate (AP) lobes stained with H&E. (A-B) The DLP lobes excised from mice with (Ab) EAP showed a significant increase in inflammation compared to (Ac) control cohorts. (C-D) Likewise, (Cb) the DLP lobes excised from TRPV1 KO mice with EAP (TRPV1 KO-EAP) demonstrated robust inflammation and leukocyte infiltration (red arrows), compared to respective (Ca) controls (TRPV1 KO-Naive). (A-D) In contrast, the (Ac,d; Cc,d) VP and (Ae,f; Ce,f) AP lobes lacked significant inflammation in all mice. Scale bars indicate 100 microns. Data represents the mean ± SEM. (*) denotes P<0.05.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Quantitative Proteomics, Staining, Control

Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: Active mast cells increase after prostate inflammation and the absence of TRPV1 hinders activity. (A-D) Panels show representative images of the prostate stained with toluidine blue and excised from B6 and TRPV1 KO mice with or without EAP; graphs depict quantification of mast cell numbers in the prostate for each group. (A) Although B6 with EAP showed no significant changes in total number of mast cells (white arrows) compared to control at day 20, (B) B6 mice with EAP showed an increased number of active mast cells (red arrows) compared to controls. (C-D) Prostates from mice with EAP that lack TRPV1 channels (TRPV1 KO-EAP) showed no changes in mast cell numbers or activity, compared to respective controls (TRPV1 KO-Naive). Scale bars indicate 100 microns. Data represents the mean ± SEM. (*) denotes P<0.05.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Activity Assay, Staining, Control

Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: TRPV1 expression is unaltered in the prostate of mice with EAP. (A-B) Protein analysis and immunohistochemistry of the DLP lobes showed no differences in expression of TRPV1 between B6 mice with EAP and respective controls. (A) Representative western blots and (B) densitometry data comparing TRPV1 expression in B6 mice with EAP (n=3) to control (n=3) cohorts. Data represents the mean ± SEM.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Expressing, Immunohistochemistry, Western Blot, Control

Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: ERK1/2 phosphorylation is linked to TRPV1 expression. (A) Western blot analysis and quantification of ERK1/2 phosphorylation in the lumbosacral region of the DRG (n=3) and (B) spinal cord (n=3) from mice with EAP revealed a significant increase in p-ERK1/2 expression compared to control littermates at day 20. However, (C) DRG and (D) spinal cords obtained from TRPV1 deficient mice with EAP showed no changed in ERK1/2 phosphorylation compared to control cohorts. Densitometry data represents the mean ± SEM. (*) denotes P<0.05.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Phospho-proteomics, Expressing, Western Blot, Control

Journal: The Prostate

Article Title: TRPV1 in Experimental Autoimmune Prostatitis

doi: 10.1002/pros.23913

Figure Lengend Snippet: Pelvic tactile allodynia is diminished by TRPV1 antagonist peptide. (A) Schematic shows mice treatment regime. Mice (B6) with or without EAP received intraurethral (IU) instillation (10µl) of either sterile 0.9% saline or a TRPV1 antagonist peptide (L-R4W2; 1mM) from day 20 (indicated by black arrows) to 35. (B) After initial treatment at day 20, mice with EAP that received L-R4W2 (EAP+Antagonist; n=3) treatment showed a similar response frequency to mice without EAP that received either saline (Naive+Saline; n=3) or L-R4W2 (Naive+Antagonist; n=3) at days 25, 30, and 35. However, mice with EAP that received intraurethral saline (EAP+Saline; n=3) showed increased response frequency between days 7-35. Data represents the mean ± SEM from 3 independent experiments. (*) denotes P<0.05.

Article Snippet: The catheter was attached to a 30-gauge needle mounted on a gastight micro syringe (Hamilton; No.80301) and 10μl of either 0.9% saline (sterile) or TRPV1 antagonist peptide (L-R 4 W 2 ) (1mM; Tocris; No.1577) was infused into mice with EAP and control cohorts at day 20.

Techniques: Sterility, Saline